H. Stewart Parker has resigned from the board of Targeted Genetics, a week after she stepped down as president and CEO. The Seattle-based biotech company (NASDAQ: [[ticker:TGEN]]) named her replacement as CEO, Susan Robinson, to also fill Parker’s position on the board. Parker left the company she founded as a series of setbacks in the field of gene therapy put the company in a precarious position. Targeted Genetics stock closed Friday at 32 cents a share.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
